Ignite Creation Date:
2024-07-17 @ 10:44 AM
Last Modification Date:
2024-10-26 @ 3:33 PM
Study NCT ID:
NCT06482788
Status:
RECRUITING
Last Update Posted:
2024-07-01
First Post:
2024-05-22
Brief Title:
Perioperative Treatment of Resectable Adenocarcinoma of Esophagogastric Junction by Immunotherapy Adebrelimab Combined With Chemotherapy XELOX a Prospective Single-center Feasibility Study
Sponsor:
Ruijin Hospital
Organization:
Ruijin Hospital
Study Overview
Official Title:
Perioperative Treatment of Resectable Adenocarcinoma of Esophagogastric Junction by Immunotherapy Adebrelimab Combined With Chemotherapy XELOX a Prospective Single-center Feasibility Study
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
AEGIS
Brief Summary:
The purpose of this study is to explore the effectiveness and safety of immunotherapy Adebrelimab a PD-L1 inhibitor combined with standard chemotherapy XELOX in the perioperative treatment of resectable esophagogastric junction adenocarcinoma
Detailed Description:
The study will evaluate the efficacy and safety of the immunotherapy Adebrelimab combined with standard chemotherapy XELOX in the perioperative treatment of resectable esophagogastric junction adenocarcinoma Potential study participants will be assessed for eligibility during a 28-day screening period that includes central verification of clinical stage and eligibility Eligible patients will be receive perioperative treatment with adebrelimab with XELOX Location of the primary GEJ type I vs GEJ type IIIII vs stomach and PD-L1-status CPS5 vs CPS5 Microsatellite Instability MSI-H vs MSI-L will be will be given special attention
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None